Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1982-3-22
|
pubmed:abstractText |
Vitamin D appears to influence parathyroid function indirectly through its effects on calcium metabolism rather than by a direct action of its metabolites on the parathyroid glands. In states of both secondary and primary hyperparathyroidism, the quantitative production of 1,25-(OH)2D may be determined by the prevailing concentration of serum 25-(OH)D but there appears to be some constraint that limits the formation of 1,25-0(OH)2D when the provision of its precursor exceeds the physiological. From the absence of this constraint in 'type 2 vitamin D dependency' it is inferred that it may operate through 'self-inhibition' of the renal production of 1,25-(OH)2D. It is shown that the level of serum 25-(OH)D may always exert some influence on the production of 1,25-(OH)2D and that this effect is facilitated by hyperparathyroidism. In developing vitamin D deficiency the reactive secondary hyperparathyroidism may thus function as an adaptive mechanism that sustains the level of serum 1,25-(OH)2D in the face of a diminishing serum 25-(OH)D. Failure of this adaptation and the development of a critical deficiency of 1,25-(OH)2D is regarded as the direct cause of defective mineralisation of bone. This concept would explain the absence of osteomalacia in some patients with very low levels of serum 25-(OH)D and the occurrence of defective osseous mineralisation in hypoparathyroidism.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/25-Hydroxyvitamin D 2,
http://linkedlifedata.com/resource/pubmed/chemical/Calcitriol,
http://linkedlifedata.com/resource/pubmed/chemical/Ergocalciferols,
http://linkedlifedata.com/resource/pubmed/chemical/Parathyroid Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Vitamin D
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0035-8819
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
205-9, 212-7
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:6976436-25-Hydroxyvitamin D 2,
pubmed-meshheading:6976436-Calcitriol,
pubmed-meshheading:6976436-Ergocalciferols,
pubmed-meshheading:6976436-Humans,
pubmed-meshheading:6976436-Hyperparathyroidism,
pubmed-meshheading:6976436-Hyperparathyroidism, Secondary,
pubmed-meshheading:6976436-Hypocalcemia,
pubmed-meshheading:6976436-Osteomalacia,
pubmed-meshheading:6976436-Parathyroid Hormone,
pubmed-meshheading:6976436-Vitamin D,
pubmed-meshheading:6976436-Vitamin D Deficiency
|
pubmed:year |
1981
|
pubmed:articleTitle |
Vitamin D and hyperparathyroidism: the Lumleian Lecture 1981.
|
pubmed:publicationType |
Journal Article
|